Cargando…

Proteomics Approach of Rapamycin Anti-Tumoral Effect on Primary and Metastatic Canine Mammary Tumor Cells In Vitro

Rapamycin is an antifungal drug with antitumor activity and acts inhibiting the mTOR complex. Due to drug antitumor potential, the aim of this study was to evaluate its effect on a preclinical model of primary mammary gland tumors and their metastases from female dogs. Four cell lines from our cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Lainetti, Patrícia F., Leis-Filho, Antonio F., Kobayashi, Priscila E., de Camargo, Laíza S., Laufer-Amorim, Renee, Fonseca-Alves, Carlos E., Souza, Fabiana F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956669/
https://www.ncbi.nlm.nih.gov/pubmed/33668689
http://dx.doi.org/10.3390/molecules26051213
_version_ 1783664489399320576
author Lainetti, Patrícia F.
Leis-Filho, Antonio F.
Kobayashi, Priscila E.
de Camargo, Laíza S.
Laufer-Amorim, Renee
Fonseca-Alves, Carlos E.
Souza, Fabiana F.
author_facet Lainetti, Patrícia F.
Leis-Filho, Antonio F.
Kobayashi, Priscila E.
de Camargo, Laíza S.
Laufer-Amorim, Renee
Fonseca-Alves, Carlos E.
Souza, Fabiana F.
author_sort Lainetti, Patrícia F.
collection PubMed
description Rapamycin is an antifungal drug with antitumor activity and acts inhibiting the mTOR complex. Due to drug antitumor potential, the aim of this study was to evaluate its effect on a preclinical model of primary mammary gland tumors and their metastases from female dogs. Four cell lines from our cell bank, two from primary canine mammary tumors (UNESP-CM1, UNESP-CM60) and two metastases (UNESP-MM1, and UNESP-MM4) were cultured in vitro and investigated for rapamycin IC(50). Then, cell lines were treated with rapamycin IC(50) dose and mRNA and protein were extracted in treated and non-treated cells to perform AKT, mTOR, PTEN and 4EBP1 gene expression and global proteomics by mass spectrometry. MTT assay demonstrated rapamycin IC(50) dose for all different tumor cells between 2 and 10 μM. RT-qPCR from cultured cells, control versus treated group and primary tumor cells versus metastatic tumor cells, did not shown statistical differences. In proteomics were found 273 proteins in all groups, and after data normalization 49 and 92 proteins were used for statistical analysis for comparisons between control versus rapamycin treatment groups, and metastasis versus primary tumor versus metastasis rapamycin versus primary tumor rapamycin, respectively. Considering the two statistical analysis, four proteins, phosphoglycerate mutase, malate dehydrogenase, l-lactate dehydrogenase and nucleolin were found in decreased abundance in the rapamycin group and they are related with cellular metabolic processes and enhanced tumor malignant behavior. Two proteins, dihydrolipoamide dehydrogenase and superoxide dismutase, also related with metabolic processes, were found in higher abundance in rapamycin group and are associated with apoptosis. The results suggested that rapamycin was able to inhibit cell growth of mammary gland tumor and metastatic tumors cells in vitro, however, concentrations needed to reach the IC(50) were higher when compared to other studies.
format Online
Article
Text
id pubmed-7956669
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79566692021-03-16 Proteomics Approach of Rapamycin Anti-Tumoral Effect on Primary and Metastatic Canine Mammary Tumor Cells In Vitro Lainetti, Patrícia F. Leis-Filho, Antonio F. Kobayashi, Priscila E. de Camargo, Laíza S. Laufer-Amorim, Renee Fonseca-Alves, Carlos E. Souza, Fabiana F. Molecules Article Rapamycin is an antifungal drug with antitumor activity and acts inhibiting the mTOR complex. Due to drug antitumor potential, the aim of this study was to evaluate its effect on a preclinical model of primary mammary gland tumors and their metastases from female dogs. Four cell lines from our cell bank, two from primary canine mammary tumors (UNESP-CM1, UNESP-CM60) and two metastases (UNESP-MM1, and UNESP-MM4) were cultured in vitro and investigated for rapamycin IC(50). Then, cell lines were treated with rapamycin IC(50) dose and mRNA and protein were extracted in treated and non-treated cells to perform AKT, mTOR, PTEN and 4EBP1 gene expression and global proteomics by mass spectrometry. MTT assay demonstrated rapamycin IC(50) dose for all different tumor cells between 2 and 10 μM. RT-qPCR from cultured cells, control versus treated group and primary tumor cells versus metastatic tumor cells, did not shown statistical differences. In proteomics were found 273 proteins in all groups, and after data normalization 49 and 92 proteins were used for statistical analysis for comparisons between control versus rapamycin treatment groups, and metastasis versus primary tumor versus metastasis rapamycin versus primary tumor rapamycin, respectively. Considering the two statistical analysis, four proteins, phosphoglycerate mutase, malate dehydrogenase, l-lactate dehydrogenase and nucleolin were found in decreased abundance in the rapamycin group and they are related with cellular metabolic processes and enhanced tumor malignant behavior. Two proteins, dihydrolipoamide dehydrogenase and superoxide dismutase, also related with metabolic processes, were found in higher abundance in rapamycin group and are associated with apoptosis. The results suggested that rapamycin was able to inhibit cell growth of mammary gland tumor and metastatic tumors cells in vitro, however, concentrations needed to reach the IC(50) were higher when compared to other studies. MDPI 2021-02-25 /pmc/articles/PMC7956669/ /pubmed/33668689 http://dx.doi.org/10.3390/molecules26051213 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lainetti, Patrícia F.
Leis-Filho, Antonio F.
Kobayashi, Priscila E.
de Camargo, Laíza S.
Laufer-Amorim, Renee
Fonseca-Alves, Carlos E.
Souza, Fabiana F.
Proteomics Approach of Rapamycin Anti-Tumoral Effect on Primary and Metastatic Canine Mammary Tumor Cells In Vitro
title Proteomics Approach of Rapamycin Anti-Tumoral Effect on Primary and Metastatic Canine Mammary Tumor Cells In Vitro
title_full Proteomics Approach of Rapamycin Anti-Tumoral Effect on Primary and Metastatic Canine Mammary Tumor Cells In Vitro
title_fullStr Proteomics Approach of Rapamycin Anti-Tumoral Effect on Primary and Metastatic Canine Mammary Tumor Cells In Vitro
title_full_unstemmed Proteomics Approach of Rapamycin Anti-Tumoral Effect on Primary and Metastatic Canine Mammary Tumor Cells In Vitro
title_short Proteomics Approach of Rapamycin Anti-Tumoral Effect on Primary and Metastatic Canine Mammary Tumor Cells In Vitro
title_sort proteomics approach of rapamycin anti-tumoral effect on primary and metastatic canine mammary tumor cells in vitro
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956669/
https://www.ncbi.nlm.nih.gov/pubmed/33668689
http://dx.doi.org/10.3390/molecules26051213
work_keys_str_mv AT lainettipatriciaf proteomicsapproachofrapamycinantitumoraleffectonprimaryandmetastaticcaninemammarytumorcellsinvitro
AT leisfilhoantoniof proteomicsapproachofrapamycinantitumoraleffectonprimaryandmetastaticcaninemammarytumorcellsinvitro
AT kobayashipriscilae proteomicsapproachofrapamycinantitumoraleffectonprimaryandmetastaticcaninemammarytumorcellsinvitro
AT decamargolaizas proteomicsapproachofrapamycinantitumoraleffectonprimaryandmetastaticcaninemammarytumorcellsinvitro
AT lauferamorimrenee proteomicsapproachofrapamycinantitumoraleffectonprimaryandmetastaticcaninemammarytumorcellsinvitro
AT fonsecaalvescarlose proteomicsapproachofrapamycinantitumoraleffectonprimaryandmetastaticcaninemammarytumorcellsinvitro
AT souzafabianaf proteomicsapproachofrapamycinantitumoraleffectonprimaryandmetastaticcaninemammarytumorcellsinvitro